查看購物車
  • Simplified Chinese
  • English
亞太地區疫苗佐劑市場預測至 2030 年 - 區域分析 - 按佐劑類別（礦物鹽佐劑、乳液佐劑、脂質體佐劑等）和類型（人用疫苗佐劑和獸用疫苗佐劑）分類
市場調查報告書
商品編碼
1666307

亞太地區疫苗佐劑市場預測至 2030 年 - 區域分析 - 按佐劑類別（礦物鹽佐劑、乳液佐劑、脂質體佐劑等）和類型（人用疫苗佐劑和獸用疫苗佐劑）分類

Asia Pacific Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Adjuvant Class (Mineral Salt Adjuvant, Emulsion Adjuvant, Liposome Adjuvant, and Others) and Type (Human Vaccine Adjuvant and Veterinary Vaccine Adjuvant)
出版日期: | 出版商: The Insight Partners | 英文 88 Pages | 訂單完成後即時交付

價格

2022年亞太地區疫苗佐劑市值為5.1807億美元，預計2030年將達到15.4643億美元；預計 2022 年至 2030 年的複合年成長率為 14.6%。

生物技術和免疫學的進步推動亞太疫苗佐劑市場的發展

由於對增強疫苗效力的需求不斷成長以及疫苗應用範圍擴大到傳統傳染病之外，疫苗佐劑市場帶來了重大機會。隨著新病原體的出現和現有病原體的進化，對能夠增強免疫反應並提供更廣泛保護的佐劑的需求日益增加。生物技術和免疫學的進步推動了佐劑配方的創新，為預防和治療疫苗提供了新的解決方案。此外，全球疫苗接種計劃的興起和疫苗研究資金的增加也推動了市場成長。專注於開發安全性更高、效力更高的佐劑的公司有能力利用這個不斷擴大的市場。與研究機構和生物技術公司的策略夥伴關係和合作可以進一步增加這個充滿活力的領域的機會，使其成為一個有希望的投資和發展領域。

亞太地區疫苗佐劑市場概況

亞太疫苗佐劑市場細分為中國、日本、印度、澳洲、韓國和亞太其他地區。中國公司合作生產佐劑疫苗等策略性措施推動了市場的發展。例如，2020 年 4 月，Dynavax Technologies Corporation 宣布與中國生物製藥公司 Sinovac 合作開發 CpG 1018 佐劑。 CpG 1018 是美國食品藥物管理局 (FDA) 批准的成人乙肝疫苗 HEPLISAV-B [佐劑型乙肝疫苗 (重組)] 中使用的佐劑，可增強疫苗免疫反應。因此，中國製造商在採購佐劑疫苗方面的合作與夥伴關係等策略發展是推動市場積極成長的獨立因素。

亞太地區疫苗佐劑市場收入及 2030 年預測（百萬美元）

亞太地區疫苗佐劑市場區隔

亞太地區疫苗佐劑市場分為佐劑類別、類型和國家。

依佐劑類別，亞太疫苗佐劑市場分為礦物鹽佐劑、乳液佐劑、脂質體佐劑等。 2022 年，礦物鹽佐劑部分佔據亞太地區疫苗佐劑市場的最大佔有率。

根據類型，亞太地區疫苗佐劑市場分為人用疫苗佐劑和獸用疫苗佐劑。 2022 年，人類疫苗佐劑部分在亞太疫苗佐劑市場中佔有較大的佔有率。

依國家分類，亞太疫苗佐劑市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。 2022 年中國佔據亞太疫苗佐劑市場的主導佔有率。

Croda International Plc； CSL有限公司；葛蘭素史克公司；夏威夷生物技術公司； InvivoGen SAS； Novavax Inc； Phibro 動物健康公司；和 SPI Pharma Inc 是亞太地區疫苗佐劑市場的一些領先公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 關鍵見解

第3章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：亞太地區疫苗佐劑市場 - 主要市場動態

  • 亞太地區疫苗佐劑市場 - 主要市場動態
  • 市場促進因素
    • 傳染病爆發和疫情數量不斷增加
    • 獸用疫苗佐劑的核准
  • 市場限制
    • 產品召回和不良影響
  • 市場機會
    • 生物技術和免疫學的進展
  • 未來趨勢
    • 技術進步
  • 促進因素和限制因素的影響：

第 5 章：疫苗佐劑市場 - 亞太市場分析

  • 亞太地區疫苗佐劑市場 - 收入及 2030 年預測
  • 亞太地區疫苗佐劑市場預測與分析

第 6 章：亞太地區疫苗佐劑市場分析 - 按佐劑類別

  • 概述
  • 礦物鹽佐劑
  • 乳化助劑
  • 脂質體佐劑
  • 其他

第 7 章：亞太地區疫苗佐劑市場分析 - 按類型

  • 人類疫苗佐劑
  • 獸用疫苗佐劑

第 8 章：亞太地區疫苗佐劑市場 - 國家分析

  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區

第9章：產業格局

  • 概述
  • 疫苗佐劑市場的成長策略
  • 有機發展
    • 概述
  • 無機發展
    • 概述

第10章：公司簡介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Hawaii Biotech Inc
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 11 章：附錄

Product Code: BMIRE00031082

The Asia Pacific vaccine adjuvants market was valued at US$ 518.07 million in 2022 and is expected to reach US$ 1,546.43 million by 2030; it is estimated to register a CAGR of 14.6% from 2022 to 2030 .

Advancements in Biotechnology and Immunology Boost Asia Pacific Vaccine Adjuvants Market

The vaccine adjuvants market presents significant opportunities due to the growing demand for enhanced vaccine efficacy and the expansion of vaccine applications beyond traditional infectious diseases. As new pathogens emerge and existing ones evolve, there is an increasing need for adjuvants that can boost immune responses and provide broader protection. Advancements in biotechnology and immunology are driving innovation in adjuvant formulations, offering novel solutions for both preventive and therapeutic vaccines. Additionally, the rise in global vaccination programs and increased funding for vaccine research are fueling market growth. Companies focusing on developing adjuvants with improved safety profiles and higher effectiveness are well-positioned to capitalize on this expanding market. Strategic partnerships and collaborations with research institutions and biotechnology firms can further enhance opportunities in this dynamic field, making it a promising area for investment and development.

Asia Pacific Vaccine Adjuvants Market Overview

The Asia Pacific vaccine adjuvant market has been segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Strategic initiatives, such as collaborations between Chinese companies to produce adjuvant vaccines, drive the market. For instance, in April 2020, Dynavax Technologies Corporation announced a collaboration with Chinese biopharmaceutical company Sinovac to develop CpG 1018 adjuvant. CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the US Food and Drug Administration (FDA) to increase vaccine immune response. Therefore, strategic developments such as collaboration and partnerships by the Chinese manufacturers for procuring adjuvanted vaccines is a standalone factor responsible for positive market growth.

Asia Pacific Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Vaccine Adjuvants Market Segmentation

The Asia Pacific vaccine adjuvants market is categorized into adjuvant class, type, and country.

Based on adjuvant class, the Asia Pacific vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Asia Pacific vaccine adjuvants market share in 2022.

By type, the Asia Pacific vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Asia Pacific vaccine adjuvants market in 2022.

By country, the Asia Pacific vaccine adjuvants market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific vaccine adjuvants market share in 2022.

Croda International Plc; CSL Ltd; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific vaccine adjuvants market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Vaccine Adjuvants Market - Key Market Dynamics

  • 4.1 Asia Pacific Vaccine Adjuvants Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 4.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 4.3 Market Restraints
    • 4.3.1 Product Recalls and Adverse Effects
  • 4.4 Market Opportunity
    • 4.4.1 Advancements in Biotechnology and Immunology
  • 4.5 Future Trends
    • 4.5.1 Technological Advancements
  • 4.6 Impact of Drivers and Restraints:

5. Vaccine Adjuvants Market -Asia Pacific Market Analysis

  • 5.1 Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 5.2 Asia Pacific Vaccine Adjuvants Market Forecast and Analysis

6. Asia Pacific Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 6.1 Overview
  • 6.2 Mineral Salt Adjuvant
    • 6.2.1 Overview
    • 6.2.2 Mineral Salt Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Emulsion Adjuvant
    • 6.3.1 Overview
    • 6.3.2 Emulsion Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Liposome Adjuvant
    • 6.4.1 Overview
    • 6.4.2 Liposome Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Others
    • 6.5.1 Overview
    • 6.5.2 Others: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Vaccine Adjuvants Market Analysis - by Type

  • 7.1 Human Vaccine Adjuvant
    • 7.1.1 Overview
    • 7.1.2 Human Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Veterinary Vaccine Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Veterinary Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Vaccine Adjuvants Market -Country Analysis

  • 8.1 Asia Pacific
    • 8.1.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 8.1.1.1 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.1 Overview
        • 8.1.1.1.2 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.1 Overview
        • 8.1.1.2.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.3 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.1 Overview
        • 8.1.1.3.2 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.4 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.1 Overview
        • 8.1.1.4.2 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.5 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.1 Overview
        • 8.1.1.5.2 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
      • 8.1.1.6 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.1 Overview
        • 8.1.1.6.2 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 8.1.1.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 8.1.1.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type

9. Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Vaccine Adjuvants Market
  • 9.3 Organic Developments
    • 9.3.1 Overview
  • 9.4 Inorganic Developments
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 SPI Pharma Inc
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 GSK Plc
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 CSL Ltd
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Hawaii Biotech Inc
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 InvivoGen SAS
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Croda International Plc
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Novavax Inc
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Phibro Animal Health Corp
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners

List Of Tables

  • Table 1. Asia Pacific Vaccine Adjuvants Market Segmentation
  • Table 2. Asia Pacific Vaccine Adjuvants Market Revenue and Forecasts To 2030 (US$ Million)
  • Table 3. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 4. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 5. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 6. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 7. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 8. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 9. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 10. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 11. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 12. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 13. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 14. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 15. Organic Developments Done by Companies
  • Table 16. Inorganic Developments Done by Companies

List Of Figures

  • Figure 1. Asia Pacific Vaccine Adjuvants Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Asia Pacific Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 4. Asia Pacific Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 5. Mineral Salt Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 6. Emulsion Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Liposome Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Others: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Asia Pacific Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 10. Human Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Veterinary Vaccine Adjuvant: Asia Pacific Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Asia Pacific: Vaccine Adjuvants Market - Revenue by Key Countries 2022 (US$ Million)
  • Figure 13. Asia Pacific: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 14. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 15. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 16. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 17. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Growth Strategies in the Vaccine Adjuvants Market